Prognostic fine needle aspiration biopsy of uveal melanoma: Molecular and genetic factors of metastasis risk

Introduction. Molecular genetic testing is actively used for prognostication in patients with uveal melanoma (UM). Tissue for genetic analysis may be obtained either by surgical excision or through fine-needle aspiration biopsy (FNAB). Performing genetic testing and FNAB in each institution can differ in surgical techniques and laboratory methodologies.

Aim. To present our own experience of performing FNAB-based molecular genetic testing for prognostication in patients with uveal melanoma.

Materials and methods. Prognostic FNAB (n = 151) were combined with brachytherapy or stereotactic surgery. Genetic testing was performed by methods based on polymerase chain reaction (GNAQ, GNA11, EIF1AX and SF3B1 mutations) and fluorescence in situ hybridization (copy numbers of PPARG and MYC genes); cytology of FNAB material was also assessed.

Results. Fine-needle aspiration biopsy material was informative in 91 % of cases. At the median follow-up of 36 months, 12 cases of distant metastases were detected. Occurrence of the assessed mutations and copy numbers were related to other representative studies. PPARG deletion was shown to be a significant prognostic factor for metastasis-free survival (p <0,01), which was demonstrated for the first time; EIF1AX and SF3B1 mutations, MYC amplification and cytological class were not shown to be significantly associated with survival in our study.

Conclusion. FNAB-based molecular genetic testing for prognostication in patients with uveal melanoma was shown to be a reliable and highly informative approach. Some of the prognostic factors need to be evaluated further with longer follow-up.

1. Hoiom V., Helgadottir H. The genetics of uveal melanoma: current in sights. Appl Clin Genet 2016;9:147–55. DOI: 10.2147/TACG.S69210

2. Olopade O.I., Pichert G. Cancer genetics in oncology practice. Ann Oncol 2001;12(7):895–908. DOI: 10.2147/TACG.S69210

3. Chattopadhyay C., Kim D.W., Gombos D.S. et al. Uveal melanoma: from diagnosis to treatment and the science in between. Cancer 2016;122(15):2299–312. DOI: 10.2147/TACG.S69210

4. Royer-Bertrand B., Torsello M., Rimoldi D. et al. Comprehensive Genetic landscape of uveal melanoma by whole-genome sequencing. Am J Hum Genet 2016;99(5):1190–8. DOI: 10.1016/j.ajhg.2016.09.008

5. Jager M.J., Shields C.L., Cebulla C.M. et al. Uveal melanoma. Nat Rev Dis Prim 2020;6(1):24. DOI: 10.1038/s41572-020-0158-0

6. Egger E., Zografos L., Schalenbourg A. et al. Eye retention after proton beam radiotherapy for uveal melanoma. Int J Radiat Oncol 2003;55(4):867–80. DOI: 10.1016/S0360-3016(02)04200-1

7. Shields C.L., Shields J.A., Perez N. et al. Primary transpupillary thermotherapy for small choroidal melanoma in 256 consecutive cases: outcomes and limitations. Ophthalmology 2002;109(2):225– 34. DOI: 10.1016/S0161-6420(01)00902-2

8. Kaliki S., Shields C., Shields J. Uveal melanoma: estimating prognosis. Indian J Ophthalmol 2015;63(2):93. DOI: 10.4103/0301-4738.154367

9. Radivoyevitch T., Zabor E.C., Singh A.D. Uveal melanoma: longterm survival. PLoS One 202;16(5):e0250939. DOI: 10.1371/journal.pone.0250939

10. Singh A.D., Zabor E.C., Radivoyevitch T. Estimating сured fractions of uveal melanoma. JAMA Ophthalmol 202;139(2):174–81. DOI: 10.1001/jamaophthalmol.2020.5720

11. Shain A.H., Bagger M.M., Yu R. et al. The genetic evolution of metastatic uveal melanoma. Nat Genet 2019;51(7):1123–30. DOI: 10.1038/s41588-019-0440-9

12. Shields C.L., Ganguly A., Bianciotto C.G. et al. Prognosis of uveal melanoma in 500 cases using genetic testing of fine-needle aspiration biopsy specimens. Ophthalmology 2011;118(2):396–401. DOI: 10.1016/j.ophtha.2010.05.023

13. Zaretsky A.R., Yarovaya V.A., Chudakova L.V. et al. Experience of molecular testing of stage I–III uveal melanoma in conservative and surgical treatment. Voprosy onkologii = Questions of Oncology 2018;5:625–32. (In Russ.).

14. Dogrusöz M., Jager M.J. Genetic prognostication in uveal melanoma. Acta Ophthalmol 2018;96(4):331–47. DOI: 10.1111/aos.13580

15. Onken M.D., Worley L.A., Char D.H. et al. Collaborative Ocular Oncology Group report number 1: prospective validation of a multigene prognostic assay in uveal melanoma. Ophthalmology 2012;8(119):1596–603. DOI: 10.1016/j.ophtha.2012.02.017

16. Jager M.J., Brouwer N.J., Esmaeli B. The cancer genome atlas project: an integrated molecular view of uveal melanoma. Ophthalmology 2018;125(8):1139–42. DOI: 10.1016/j.ophtha.2018.03.011

17. Robertson A.G., Shih J., Yau C. et al. Integrative analysis identifies four molecular and clinical subsets in uveal melanoma. Cancer Cell 2017;32(2):204–20.e15. DOI: 10.1016/j.ccell.2017.07.003

18. McCannel T.A., Chang M.Y., Burgess B.L. Multi-Year follow-up of fine-needle aspiration biopsy in choroidal melanoma. Ophthalmology 2012;119(3):606–10. DOI: 10.1016/j.ophtha.2011.08.046

19. Yarovaya V.A., Yarovoy A.A., Korobov E.N. et al. Molecular testing of uveal melanoma. Nahodki. Sovremennye tekhnologii v oftal’mologii = Finds. Modern technologies in ophthalmology. 2018;(4):297–9. (In Russ.).

20. Levashov I.A., Yarovoy A.A., Yarovaya V.A. et al. Assessment of the risk of metastasis during the “prognostic” fine needle aspiration biopsy of uveal melanoma. Zlokachestvennye opuholi = Malignant tumors 2022;12(2):29–35. (In Russ.). DOI: 10.18027/2224-50572022-12-2-29-35

21. Dogrusöz M., Jager M.J. Genetic prognostication in uveal melanoma. Acta Ophthalmol 2018;96(4):331–47. DOI: 10.1111/aos.13580

22. Sellam A., Desjardins L., Barnhill R. et al. Fine needle aspiration biopsy in uveal melanoma: technique, complications, and outcomes. Am J Ophthalmol 2016;162:28–34.e1. DOI: 10.1016/j.ajo.2015.11.005

23. Singh A.D., Medina C.A., Singh N. et al. Fine-needle aspiration biopsy of uveal melanoma: outcomes and complications. Br J Ophthalmol 2016;100(4):456–62. DOI: 10.1136/bjophthalmol-2015-306921

24. Yarovaya V.A., Shatskikh A.V., Zaretsky A.R. et al. Prognostic value of the cell type of uveal melanoma. Arhiv patologii = Pathology archive 2021;83(4):14. (In Russ.). DOI: 10.17116/patol20218304114

25. Finn A.P., Materin M.A., Mruthyunjaya Р. Choroidal tumor biopsy: a review of the current state and a glance into future techniques. Retina 2018;38(1):S79–87. DOI: 10.1097/IAE.0000000000001997

26. Augsburger J.J., Corrêa Z.M., Schneider S. et al. Diagnostic transvitreal fine-needle aspiration biopsy of small melanocytic choroidal tumors in nevus versus melanoma category. Trans Am Ophthalmol Soc 2002;100:225–32.

27. Cohen V.M.L., Dinakaran S., Parsons M.A. et al. Transvitreal fine needle aspiration biopsy: the influence of intraocular lesion size on diagnostic biopsy result. Eye 2001;15(2):143–7. DOI: 10.1038/eye.2001.48

28. Yavuzyigitoglu S., Koopmans A.E., Verdijk R.M. et al. Uveal melanomas with SF3B1 mutations. Ophthalmology 2016;123(5):1118–28. DOI: 10.1016/j.ophtha.2016.01.023

29. Parrella P., Caballero O.L., Sidransky D. et al. Detection of c-myc amplification in uveal melanoma by fluorescent in situ hybridization. Invest Ophthalmol Vis Sci 2001;42(8):1679–84. PMID 11431428

30. Souri Z., Wierenga A.P.A., van Weeghel C. et al. Loss of BAP1 is associated with upregulation of the NFkB Pathway and Increased HLA class i expression in uveal melanoma. Cancers (Basel) 2019;11(8):1102. DOI: 10.3390/cancers11081102

31. Shoushtari A.N., Carvajal R.D. GNAQ and GNA11 mutations in uveal melanoma. Melanoma Res 2014;24(6):525–34. DOI: 10.1097/CMR.0000000000000121

32. Paul E.V., Parnell B.L., Fraker M. Prognosis of malignant melanomas of the choroid and ciliary body. Int Ophthalmol Clin 1962;2(2):387–402. DOI: 10.1097/00004397-19620600000007

33. Callender Colonel G.R., Wilder H.C., Ash J.E. Five hundred melanomas of the choroid and ciliary body followed five years or longer. Am J Ophthalmol 1942;25(8):962–7. DOI: 10.1016/S00029394(42)90595-6

34. Sidawy M.K., Del Vecchio D.M., Knoll S.M. Fine-needle aspiration of thyroid nodules. Cancer 1997;25;81(4):253–9. DOI: 10.1002/(SICI)1097-0142

35. De Lange M.J., Nell R.J., van der Velden P.A. Scientific and clinical implications of genetic and cellular heterogeneity in uveal melanoma. Mol Biomed 2021;2(1):25. DOI: 10.1186/s43556-02100048-x

36. Char D.H., Kroll S.M., Miller T. et al. Irradiated uveal melanomas: cytopathologic correlation with prognosis. Am J Ophthalmol 1996;122(4):509–13. DOI: 10.1016/S0002-9394(14)72110-5